Literature DB >> 24623741

Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.

V H M Tsang1, T Dwight, D E Benn, G Y Meyer-Rochow, A J Gill, M Sywak, S Sidhu, D Veivers, C M Sue, B G Robinson, R J Clifton-Bligh, N R Parker.   

Abstract

miR-210 is a key regulator of response to hypoxia. Pheochromocytomas (PCs) and paragangliomas (PGLs) with germline SDHx or VHL mutations have pseudohypoxic gene expression signatures. We hypothesised that PC/PGLs containing SDHx or VHL mutations, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours (GISTs), would overexpress miR-210 relative to non-SDH or -VHL-mutated counterparts. miR-210 was analysed by quantitative PCR in i) 39 PC/PGLs, according to genotype (one SDHA, five SDHB, seven VHL, three NF1, seven RET, 15 sporadic, one unknown) and pathology (18 benign, eight atypical, 11 malignant, two unknown); ii) 18 GISTs, according to SDHB immunoreactivity (nine SDH-deficient and nine SDH-proficient) and iii) two novel SDHB-mutant neurosphere cell lines. miR-210 was higher in SDHx- or VHL-mutated PC/PGLs (7.6-fold) compared with tumours without SDHx or VHL mutations (P=0.0016). miR-210 was higher in malignant than in unequivocally benign PC/PGLs (P=0.05), but significance was lost when benign and atypical tumours were combined (P=0.08). In multivariate analysis, elevated miR-210 was significantly associated with SDHx or VHL mutation, but not with malignancy. In GISTs, miR-210 was higher in SDH-deficient (median 2.58) compared with SDH-proficient tumours (median 0.60; P=0.0078). miR-210 was higher in patient-derived neurosphere cell lines containing SDHB mutations (6.5-fold increase) compared with normal controls, in normoxic conditions (P<0.01). Furthermore, siRNA-knockdown of SDHB in HEK293 cells increased miR-210 by 2.7-fold (P=0.001) under normoxia. Overall, our results suggest that SDH deficiency in PC, PGL and GISTs induces miR-210 expression and substantiates the role of aberrant hypoxic-type cellular responses in the development of these tumours.

Entities:  

Keywords:  gastrointestinal stromal tumour; miR-210; paraganglioma; pheochromocytoma; succinate dehydrogenase

Mesh:

Substances:

Year:  2014        PMID: 24623741     DOI: 10.1530/ERC-13-0519

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  15 in total

1.  Role of miR-101 in pheochromocytoma patients with SDHD mutation.

Authors:  Ligeng Zong; Lizhen Meng; Ruhui Shi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  The role of miRNAs in the pheochromocytomas.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-10-13

3.  MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.

Authors:  Samantha M Ruff; Reed I Ayabe; Parisa Malekzadeh; Meghan L Good; Michael M Wach; Melissa K Gonzales; Amit Tirosh; Naris Nilubol; Karel Pacak; Electron Kebebew; Dhaval Patel
Journal:  J Surg Res       Date:  2019-05-27       Impact factor: 2.192

4.  MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism.

Authors:  Vince Kornél Grolmusz; Katalin Borka; Annamária Kövesdi; Kinga Németh; Katalin Balogh; Csaba Dékány; András Kiss; Anna Szentpéteri; Beatrix Sármán; Anikó Somogyi; Éva Csajbók; Zsuzsanna Valkusz; Miklós Tóth; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Virchows Arch       Date:  2017-06-08       Impact factor: 4.064

5.  Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.

Authors:  Suman Ghosal; Shaoli Das; Ying Pang; Melissa K Gonzales; Thanh-Truc Huynh; Yanqin Yang; David Taieb; Joakim Crona; Uma T Shankavaram; Karel Pacak
Journal:  Int J Cancer       Date:  2019-10-11       Impact factor: 7.316

6.  Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.

Authors:  Edward Kim; Michael Jp Wright; Loretta Sioson; Talia Novos; Anthony J Gill; Diana E Benn; Christopher White; Trisha Dwight; Roderick J Clifton-Bligh
Journal:  Mol Genet Metab Rep       Date:  2016-12-30

7.  Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.

Authors:  Anna Merlo; Cristóbal Bernardo-Castiñeira; Inés Sáenz-de-Santa-María; Ana S Pitiot; Milagros Balbín; Aurora Astudillo; Nuria Valdés; Bartolomé Scola; Raquel Del Toro; Simón Méndez-Ferrer; José I Piruat; Carlos Suarez; María-Dolores Chiara
Journal:  Oncotarget       Date:  2017-01-24

8.  Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.

Authors:  Bruna Calsina; Luis Jaime Castro-Vega; Rafael Torres-Pérez; Lucía Inglada-Pérez; Maria Currás-Freixes; Juan María Roldán-Romero; Veronika Mancikova; Rocío Letón; Laura Remacha; María Santos; Nelly Burnichon; Charlotte Lussey-Lepoutre; Elena Rapizzi; Osvaldo Graña; Cristina Álvarez-Escolá; Aguirre A de Cubas; Javier Lanillos; Alfonso Cordero-Barreal; Ángel M Martínez-Montes; Alexandre Bellucci; Laurence Amar; Fabio Luiz Fernandes-Rosa; María Calatayud; Javier Aller; Cristina Lamas; Júlia Sastre-Marcos; Letizia Canu; Esther Korpershoek; Henri J Timmers; Jacques Wm Lenders; Felix Beuschlein; Martin Fassnacht-Capeller; Graeme Eisenhofer; Massimo Mannelli; Fátima Al-Shahrour; Judith Favier; Cristina Rodríguez-Antona; Alberto Cascón; Cristina Montero-Conde; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

Review 9.  Heritable Cancer Syndromes Related to the Hypoxia Pathway.

Authors:  John Clark Henegan; Christian R Gomez
Journal:  Front Oncol       Date:  2016-03-22       Impact factor: 6.244

10.  MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.

Authors:  Zi-Wen Long; Jiang-Hong Wu; Ya-Nong Wang; Ye Zhou
Journal:  Mol Cells       Date:  2018-06-14       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.